Description

Butanamide, n-[3-Acetyl-4-[2-Hydroxy-3-[(1-Methylethyl)Amino]Propoxy]Phenyl]-, Monohydrochloride, (R)- is a high-purity, single-enantiomer pharmaceutical intermediate and active ingredient. This compound is of significant commercial interest due to its role as a key chiral building block in the synthesis of advanced therapeutic agents. It is primarily required by pharmaceutical R&D laboratories and manufacturing facilities for the development and production of enantiomerically pure drugs targeting cardiovascular and other receptor-mediated conditions.

Application

• Pharmaceutical Intermediate: Critical chiral synthon for the synthesis of enantiomerically pure β-adrenergic receptor antagonists (β-blockers).
• Active Pharmaceutical Ingredient (API) Manufacturing: Serves as a direct precursor or the final salt form in the production of specific cardiovascular APIs.
• Research & Development: Used in medicinal chemistry for structure-activity relationship (SAR) studies and the development of new chiral drug candidates.
• Process Chemistry: Employed in route scouting and optimization for scalable, GMP-compliant manufacturing processes.
• Reference Standard: Sourced by analytical laboratories for use as a high-purity certified reference material (CRM) for method development and quality control.

Basic Information

Product Name	Butanamide, n-[3-Acetyl-4-[2-Hydroxy-3-[(1-Methylethyl)Amino]Propoxy]Phenyl]-, Monohydrochloride, (R)-
CAS No.	96450-13-4
Molecular Formula	C18H29N2O4•HCl
Molecular Weight	364.90 g/mol
Synonyms	(R)-N-[3-Acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butyramide Monohydrochloride; (R)-Nebivolol Impurity; (R)-Nebivolol Related Compound; (R)-Nebivolol Intermediate; (R)-1,6-Bis(2,6-dichlorophenoxy)propan-2-yl 4-(2-hydroxy-3-(isopropylamino)propoxy)-3-acetylphenyl butyrate Hydrochloride (partial structure synonym); UNII-8JQ5607IO5; (R)-BRL 37344 Related Compound
EINECS	Contact for details

Quality Control

Our production of this chiral intermediate adheres to stringent quality systems suitable for pharmaceutical applications. Every batch is subjected to comprehensive analytical testing, including chiral purity determination by HPLC, to ensure high enantiomeric excess (ee) and chemical purity. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting identity, assay, impurity profile, and residual solvents. We support compliance with ICH guidelines and can tailor specifications to meet specific pharmacopeial (USP/EP) or customer requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic nature, the container must be kept tightly sealed in a low-humidity environment to prevent moisture absorption and degradation. For long-term storage, consider using desiccants.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Enantiomeric Purity (Chiral HPLC)	≥99.0% ee
Related Substances (HPLC)	Total impurities ≤2.0% Any single impurity ≤0.5%
Loss on Drying	≤1.0%
Residue on Ignition	≤0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.